Outset Medical 2026 Stifel Healthcare Conference
Review the key takeaways and the transcript of this earnings call.
Transcript
Preview the first fifteen paragraphs, organized by speaker.
Alrighty. Good afternoon to our first session of the afternoon. I am thrilled to welcome the Outset Medical team, Leslie Trigg, Chairman and CEO, to my left, Renee Gaeta, Chief Financial Officer, to Leslie's left. It is great to have you both back here. I have had the privilege of covering Outset since the 2020 IPO, and I continue to believe even more strongly today that Outset's Tablo hemodialysis system is uniquely compelling technology that continues to, I started to say the potential to transform, but is transforming traditional care to a much better model, and to hear all about that. Thank you both for being here.
Thank you. I thought that, Leslie, we would start off by talking about the sort of wonderfully thrilling headline at this press release I have in my hand.
It says, "HHS launches landmark national plan to transform kidney care in America." This is October 20th. Health and Human Services put this out. It basically talks about a department-wide strategy focused on revitalizing American kidney care. I have got a big picture question to start. How radical, how important, how transformative is this initiative by HHS?
Yeah. Well, we were obviously really delighted to see that as well, and it follows a 2019 executive order that happened in the first Trump administration with a similar commitment, particularly around encouraging the use of home dialysis. Back in 2019, they were also very interested in transplant, and I think that interest also continues today. What was new about this particular announcement was also the HHS acknowledgment that there are market forces and market practices that perhaps have made new innovation and access to new innovation or new settings and channels of care more difficult.
On top of HHS reaffirming its interest in encouraging home dialysis, it also talked about finding ways to encourage the adoption of new technologies, of which Tablo is one, and of course, also then introduced this concept of maybe there are some structural changes or improvements that should be made and hinted might be made to ultimately give patients better access to care and better patient choice to where they want to receive dialysis. So we were very encouraged by it. Let's see what policies come out of it. That's step two. What sort of policies are they actually going to effectuate before we get too excited about it? But it certainly aligns very well with our mission and could be a potential tailwind and upside for us moving forward.
As you say, it's not clear what next steps are and when they'll happen, but does the election or the election outcome or the political excitement ahead, shall we say, in the next couple of years in Washington, does that make you feel less optimistic that something really will get done, or how are you thinking about it?
Well, I think there's probably two ways to look at it, probably more than two.
I'm sure. But two that come to mind.
On the one hand, one way to look at it is we may, let's say, we may have an administration change two years from now, and in that sense, it actually could create some urgency. "Hey, let's try to actually- Oh.
get policy out there before our turn at the wheel ends." On the other hand, what we have observed is that transformation in kidney care has bipartisan appeal and a lot of bipartisan interest. I have not particularly ever viewed it as Democratic or Republican. I've seen both sides of the aisle examining dialysis care for a long time and wondering why it hasn't changed. So in that sense, even if the administration changes or doesn't change, we would expect to see continued congressional and White House administration support for creating new options for patients.
One other separate, unrelated big picture question. I know it's hard to ask you about capital spending at hospitals. I mean, you have a very narrow view window into that. But I've had a number of conversations with physicians lately, and I get the sense that hospital budgets are tightening. Just at the high level, is this something that you're concerned about as we think about the rest of the year and into next year? Is this something that we should be worried about on your behalf, or how are you thinking about that?
Subject to change, right? Because we never know what's around the next corner.
Right. But as we sit here today, that's not at the top of our worry list, nor is it something that we are hearing a lot about with regard to Tablo and insourcing of dialysis.
I do spend a lot of time in the field because I enjoy it, and I always want to make sure we're as close as we can be to the customer, and that hasn't come up for us. Now, that might be particular to what we do. As a reminder, our core value proposition is cost reduction. As hospitals are maybe feeling the pinch on the top line, whether it's changes in Medicare, Medicaid, NIH research funding, whatever it might be, what we are hearing a lot about is more hospitals turning to the bottom line.
The certainty around cost cutting feels better sometimes in climates like this than maybe what do you have to believe around trying to generate more top line revenue. I think because insourcing with Tablo does provide and drive a very, very significant, like 50+% cost reduction, we might be an evergreen story that's just become greener in this kind of climate.
FULL TRANSCRIPT
Continue the full translated transcript in StockNow.
Access every statement, the English original, and speaker-by-speaker history with StockNow Pro.
View the full transcript with ProCall participants
4 people spoke on this call — only 2 are shown here.
PARTICIPANT LIST
View participant details in StockNow.
Log in to see executives and analysts, their roles, and complete speaking history.
Log in to view all participantsKeep exploring
